ライフサイエンスコーパス: glycolic acid

1 e response compared with poly(lactic acid-co-glycolic acid).

2 ive poly-beta amino ester and poly lactic-co-glycolic acid.

3 cord of clinical translation, poly(lactic-co-glycolic) acid.

4 ant, and plasticizer solvents, polylactic-co-glycolic acid (30% by solids volume), and regolith simul

5 SNAP) was encapsulated within poly(lactic-co-glycolic acid) 50:50 (PLGA) microspheres by using a soli

6 ability of Fe(CN)6(3-) to oxidize DHEThDP to glycolic acid along with ThDP regeneration.

7 When biodegradable polymers poly(lactic-co-glycolic) acid and polylactic acid were included in the

8 system containing a blend of poly(lactic-co-glycolic acid) and a representative poly(beta-amino) est

9 cles that perform better than poly(lactic-co-glycolic acid) and iron oxide, two commonly studied mate

10 tion of diblock copolymers of poly(lactic-co-glycolic acid) and polyethylene glycol (PLGA-PEG) using

11 o 50% (w/w) sirolimus drug in poly(lactic-co-glycolic acid) and were prepared on both MP35N metal all

12 to undergo rapid oxidation to form glyoxal, glycolic acid, and glyoxylic acid, but the formation of

13 icated by emulsification with poly(lactic-co-glycolic acid) as a core material and, in some cases, po

14 poly(ethylene glycol); PLGA = poly(lactic-co-glycolic acid)) assembled from small AuNRs (dimension: a

15 of aptamer (Apt)-targeted poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG) nano

16 of thermosensitive hydrogels (poly(lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(lactic-co-

17 d using biodegradable diblock poly(lactic-co-glycolic acid)-b-polyethyleneglycol and poly(lactic-co-g

18 cid)-b-polyethyleneglycol and poly(lactic-co-glycolic acid)-b-polyethyleneglycol collagen IV-targeted

19 dichloride in a biocompatible poly(lactic-co-glycolic acid)-b-polyethyleneglycol platform.

20 evant parameters, we report a poly(lactic-co-glycolic acid) based curcumin nanoparticle formulation (

21 acids liberated by the biodegradable lactic/glycolic acid-based polyester, we coincorporated into th

22 cs by blending a targeted poly(d,l-lactic-co-glycolic acid)-block (PLGA-b)-poly(ethylene glycol) (PEG

23 patible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG)

24 r and carboxyl-terminated poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) copolymer in

25 lubilization of EpoB in a poly(d,l-lactic-co-glycolic acid)-block-poly(ethylene glycol)-block-poly(d,

26 (PEG-b-PLA) micelles and poly(D,L-lactic-co-glycolic acid)-block-polyethylene glycol)-block-poly(D,L

27 e (NP) based on biodegradable poly(lactic-co-glycolic acid)-block-polyethyleneglycol functionalized w

28 carboxyl functionalization of poly(lactic-co-glycolic acid) can achieve great material homogeneity in

29 tains a core of biodegradable poly(lactic-co-glycolic acid), cholesteryl oleate, and a phospholipid b

30 nd atactic repeating sequence poly(lactic-co-glycolic acid) copolymers (RSC PLGAs) were prepared and

31 ne provide access to fully substituted alpha-glycolic acid derivatives bearing a beta-stereocenter.

32 were created by coating PLGA (poly[lactic-co-glycolic acid]) films containing test compounds with pHE

33 mpare favourably with current poly-lactic-co-glycolic acid fixation systems, however, silk-based devi

34 acid, glycolaldehyde, glyoxal, acetic acid, glycolic acid, glyceraldehyde, 2-hydroxypropanedialdehyd

35 As little as 10 pg of standard glycolic acid (glycolate) was detected in a method compr

36 nto valuable C2, C3, and C4 products such as glycolic acid, lactic acid, 2-hydroxy-3-butenoic acid, 2

37 ly(L-lactic acid) and had poly(D,L-lactic-co-glycolic acid) membranes of different molecular masses c

38 Using poly(DL-lactic acid-co-glycolic acid) microparticles (MPs) with an average diam

39 Dexamethasone-releasing PLGA poly(lactic-co-glycolic acid) microsphere/PVA (polyvinyl alcohol) hydro

40 Dexamethasone-releasing poly(lactic-co-glycolic acid) microspheres/polyvinyl alcohol hydrogel c

41 at substitution of the 5'-sulfate in 1 for a glycolic acid moiety in 2 maintains kinesin inhibition.

42 ng a quaternary stereocenter and a protected glycolic acid moiety, which are useful building blocks f

43 prepared from the bioassimilable lactic and glycolic acid monomers for biomedical applications makes

44 rating peptide (CPP)-assisted poly(lactic-co-glycolic acid nanoparticles (PLGA NPs), for improving do

45 ncapsulated in biodegradable poly (lactic-co-glycolic acid) nanoparticles (PLGA-NP), administered by

46 uch as FDA approved pegylated poly(lactic-co-glycolic acid) nanoparticles (PLGA-PEG-NP) has significa

47 mmunotherapy using CpG-coated poly(lactic-co-glycolic acid) nanoparticles containing peanut extract (

48 Poly(lactic-co-glycolic acid) nanoparticles were dispersed in aldehyde-

49 compared to similarly sized poly (lactic-co-glycolic acid) particles.

50 e poly(ethylene glycol)-block-poly(lactic-co-glycolic acid) (PEG-PLGA) copolymers have been used succ

51 radable poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) microparticles were engineered

52 growth factor (PCL-NGF) and a poly(lactic-co-glycolic acid) pellet containing glutamine (PLGA-GLN) we

53 Poly(glycolic acid) (PGA) fiber scaffolds were wrapped around

54 ting consisted of absorbable poly-lactide-co-glycolic acid (PLGA) and crystalline sirolimus deposited

55 We created coils with a 50:50 poly-dl-lactic glycolic acid (PLGA) coating that released MCP-1 at 3 di

56 boxymethyl chitosan shell and poly lactic-co-glycolic acid (PLGA) core for enhancing localized chemo-

57 self-healing capacity of poly (DL)-lactic-co-glycolic acid (PLGA) microspheres containing glycosamino

58 Lycopene-loaded polylactic-co-glycolic acid (PLGA) NPs were prepared by the same metho

59 osteoconducive apatite-coated Poly-lactic-co-glycolic acid (PLGA) scaffold for cell delivery.

60 ic acid) peptide-modified polylactic acid-co-glycolic acid (PLGA)-Chitosan nanoparticle (CSNP) for in

61 ulating econazole-impregnated poly(lactic-co-glycolic) acid (PLGA) films in poly(hydroxyethyl methacr

62 polymer coating consisting of poly(lactic-co-glycolic) acid (PLGA) microsphere dispersed in poly(viny

63 Biodegradable poly (lactic-co-glycolic) acid (PLGA) microspheres, encapsulated within

64 Poly(d,l-lactic-co-glycolic) acid (PLGA) nanoparticles containing phenolic

65 micrometer-sized agent-doped poly(lactic-co-glycolic) acid (PLGA) particles by using a single-emulsi

66 and functionalization of poly (D,L-lactic-co-glycolic) acid (PLGA) particles to enhance cell attachme

67 e) into biodegradable polymer poly(lactic-co-glycolic) acid (PLGA) using an electrojetting technique.

68 4) and TLR7/8 encapsulated in poly(lactic-co-glycolic) acid (PLGA)-based nanoparticles (NPs) induce r

69 Poly(lactic-co-glycolic)acid (PLGA) microspheres containing anti-VEGF R

70 ed after sputtering revealing poly(lactic-co-glycolic) acid(PLGA).

71 NPS were prepared using poly(lactic-co-glycolic acid) (PLGA) and chitosan.

72 articulate nanocarriers using poly(lactic-co-glycolic acid) (PLGA) and PLGA-polyethylene glycol (PLGA

73 consisting of water-insoluble poly(lactic-co-glycolic acid) (PLGA) and water-soluble polyvinylpyrroli

74 capsulate vaccine antigens in poly(lactic-co-glycolic acid) (PLGA) by simple mixing of preformed acti

75 anoparticles (CSLPHNPs) with poly (lactic-co-glycolic acid) (PLGA) core and lipid layer containing do

76 rospheres consisting of a poly(d,l-lactic-co-glycolic acid) (PLGA) core surrounded by a poly(lactic a

77 oparticles composed of PSA or poly(lactic-co-glycolic acid) (PLGA) diffused at least 3,300-fold slowe

78 aling of aqueous pores in poly(D,L-lactic-co-glycolic acid) (PLGA) drug delivery systems has been ide

79 tration with nanoparticles of poly(lactic-co-glycolic acid) (PLGA) encapsulating short interfering RN

80 Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable FDA approved po

81 iodegradable polymer films of poly(lactic-co-glycolic acid) (PLGA) is described.

82 s of 25% (w/w) sirolimus in a poly(lactic-co-glycolic acid) (PLGA) matrix and is spray-coated onto me

83 ibility of intra-articular poly(DL-lactic-co-glycolic acid) (PLGA) microparticle (MP) formulations in

84 as encapsulated in degradable poly(lactic-co-glycolic acid) (PLGA) microparticles embedded in the PVA

85 rogels were encapsulated with poly(lactic-co-glycolic acid) (PLGA) microparticles loaded with vascula

86 he scaffolds and accommodated poly(lactic-co-glycolic acid) (PLGA) microparticulate systems that cont

87 Here, two poly(lactic-co-glycolic acid) (PLGA) microsphere formulations encapsula

88 microtubes and NEP1-40 into poly (lactic-co-glycolic acid) (PLGA) microspheres, obviating the need f

89 apsulated in glucose-star poly(d,l-lactic-co-glycolic acid) (PLGA) microspheres.

90 icles (LPNs) consisting of poly(DL-lactic-co-glycolic acid) (PLGA) nanocarriers modified with the cat

91 as to evaluate the ability of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NP) to enhance lute

92 Poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) conjugated to

93 lation of the compound within poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PLGA-EtNBS) was fou

94 proteins formulated in poly-(D, L-lactic-co-glycolic acid) (PLGA) nanoparticles adjuvanted with poly

95 Here we demonstrate that poly(lactic-co-glycolic acid) (PLGA) nanoparticles carrying rapamycin,

96 Poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing dexametha

97 Copolymer poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with SA-2 pro

98 inducing adjuvant based on poly(dl-lactic-co-glycolic acid) (PLGA) nanoparticles modified with the ca

99 t how surface modification of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with peptide ligand

100 encapsulated with drug-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles.

101 Fluorescently-tagged poly(lactic-co-glycolic acid) (PLGA) NPs were loaded with BODIPY, a flu

102 ternative surface coating for poly(lactic-co-glycolic acid) (PLGA) NPs.

103 her the biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) or the biocompatible polymer polye

104 the hypothesis that inhalable poly(lactic-co-glycolic acid) (PLGA) particles of sildenafil prolong th

105 Poly (lactic-co-glycolic acid) (PLGA) supplies lactate that accelerates

106 Drug-free and drug-loaded poly(lactic-co-glycolic acid) (PLGA) sutures were fabricated by electro

107 ribe microspheres composed of poly(lactic-co-glycolic acid) (PLGA) that can encapsulate IPV along wit

108 PEI1.8k was blended with poly(lactic-co-glycolic acid) (PLGA) to enhance electrostatic cellular

109 ng" nanoparticles composed of poly(lactic-co-glycolic acid) (PLGA) with bright, spectrally defined qu

110 en as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as t

111 rofile for the degradation of poly(lactic-co-glycolic acid) (PLGA), a member of the most widely used

112 encapsulation of the drug in poly(lactic-co-glycolic acid) (PLGA), a polymer that is used in childre

113 Poly(lactic-co-glycolic acid) (PLGA), one of the most important biodegr

114 The NPs consist of poly(D,L-lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and bi

115 meter of 227nm, composed of a poly(lactic-co-glycolic acid) (PLGA)-based core coated with poly(vinyl

116 ed nanoparticles (NPs) of poly(D,L-lactic-co-glycolic acid) (PLGA)-poly(ethylene glycol) (PEG)-functi

117 with distinct functions: (i) poly(lactic-co-glycolic acid) (PLGA, P) serving as the main delivery pl

118 olyethylene glycol)-block-poly(D,L-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) sol-gels have been ex

119 ly(ethylene glycol)-block-poly(d,l-lactic-co-glycolic acid) (PLGA-b-PEG-b-PLGA) thermosensitive gel (

120 osed of end-to-end linkage of poly(lactic-co-glycolic-acid) (PLGA), polyethyleneglycol (PEG), and the

121 formulations as well as with poly(lactic-co-glycolic acid)(PLGA)-based microparticles, co-loaded wit

122 id)-b-poly(ethylene glycol)-b-poly(lactic-co-glycolic acid); PLGA-PEG-PLGA) for increasing the retent

123 nd low Mw free acid end-group poly(lactic-co-glycolic acids) (PLGAs) used to achieve continuous pepti

124 of poly(butylcyanoacrylate), poly(lactic-co-glycolic acid), poly(lactic acid) NPs, liposomes and ino

125 peripheral blood EPCs were seeded onto poly (glycolic acid)/poly (4-hydroxybutyrate) scaffolds for 5

126 ured on hydroxyapatite-coated poly(lactic-co-glycolic acid)/poly(L-lactic acid) (HA-PLGA/PLLA) scaffo

127 into a drug-encapsulating Poly dl-lactic-co-glycolic acid polymer (PLGA), via a double emulsion solv

128 a unique hexadentate-polyD,L-lactic acid-co-glycolic acid polymer chemically conjugated to PD98059,

129 S contrast agent composed of poly-lactide-co-glycolic acid polymeric (PLGA) microspheres (2-micron di

130 stinct compartments namely; poly(l-lactic-co-glycolic acid) polymeric core acting as a drug reservoir

131 PLGAs as a function of time and PLGA lactic/glycolic acid ratio.

132 nal properties were studied at two lactic to glycolic acid ratios (50:50 and 65:35).

133 an random copolymers with the same lactic to glycolic acid ratios as demonstrated by molecular weight

134 ain an ester linkage between a threonine and glycolic acid residue and an N-terminal FITC fluorophore

135 Installation of the glycolic acid residue followed by C12 epimerization.

136 Self-healing of pores in Poly(lactic-co-glycolic acid)s (PLGA) plays an important role in the en

137 lylysine around a salt-leached polylactic-co-glycolic acid scaffold that is degraded in a sodium hydr

138 orated in a uniquely designed poly(lactic-co-glycolic) acid scaffold, a clinically safe polymer, foll

139 al (3D)-printed biodegradable poly(lactic-co-glycolic acid) scaffolds (PLGA), and hydroxyapatite powd

140 Specifically labeled deuterated lactic and glycolic acid segmers were likewise prepared and polymer

141 Semisynthetic modification of its glycolic acid subunit at C14 provided the first analogs

142 he OS studied include the potassium salts of glycolic acid sulfate, hydroxyacetone sulfate, 4-hydroxy

143 a well-studied biodegradable poly(lactic-co-glycolic acid) support membrane.

144 -lactic acid) (PLA), and poly(lactic acid-co-glycolic acid) surfaces.

145 ion as a synthetic equivalent to the dipolar glycolic acid synthon, the glyoxylate anion synthon, or

146 ibes the use of silyl glyoxylates as dipolar glycolic acid synthons in a controlled oligomerization r

147 icle formulations composed of poly lactic-co-glycolic acid take too long to release encapsulated payl

148 Poly(lactic-co-glycolic acid) thin films were used to deliver FTY720, a

149 Biocompatible poly (lactic-co-glycolic acid) was selected as the polymer shell to enca

150 e developed a scaffold from variants of poly(glycolic) acid which were braided and coated with an ela

151 Nanoparticles composed of poly(lactic-co-glycolic acid), with polyethylene glycol coatings to res